摘要:

AbstractThe toxicologic, biologic, and clinical effects of recombinant interleukin-2 (IL-2) were tested in 25 patients with cancer. Escalating doses from 103to 107U/m2per day were given by either daily bolus injection (BI) or continuous infusion (CI) for 7 consecutive days. Dose-limiting toxicities included a decline in performance status, systolic hypotension, and fever, which reversed promptly with discontinuation of therapy. The maximum tolerated dose of IL-2 by BI for 7 days was 3 X 106U/m2per day and for CI was 106U/m2per day. Significant changes in the number, phenotype, and function of circulating peripheral blood lymphocytes occurred at doses>106U/m2per day by both administration schedules. With the initiation of therapy, a decline in the number of circulating peripheral blood lymphocytes (PBL) was seen in patients treated by either BI or CI. Additionally, the in vitro cytotoxic activity of these PBL against K562 was markedly decreased. Within 24 h of completing BI or CI, a rebound increase in the number of circulating PBL was seen. The phenotype of the circulating PBL after completion of treatment showed a significant (p>0.05) increase in the numbers of OKT-3+, OKT-8+, OKT-10+, OK-Ia+, OKMI +, and OKT-11 + for patients treated by CI. Those patients treated by BI had a significant increase in Ia+ and OKT-10+ cells. At IL-2 doses>105U/m2per day, the PBL obtained following treatment with rIL-2 demonstrated in vitro cytotoxic capacity against K562 target cells that was significantly enhanced over pretreatment levels. This study demonstrates that IL-2 can be given by CI or BI in a non-ICU setting with acceptable dose-dependent toxicity. Upon completion of treatment an increase in the number of activated cells could be detected. Although no clinical responses occurred, the generation of endogenous activated PBL capable of enhanced cytotoxicity is encouraging. Future studies will explore the use of multiple courses of treatment with IL-2 to determine if therapeutic efficacy can be accomplished.

ISSN:0735-7907    

DOI:10.3109/07357908909039840

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractFifteen patients with acquired immune deficiency syndrome (AIDS) and opportunistic infection, were randomized to receive treatment with either thymostimulin (TP-1) at 1 mg/kg for 14 days then weekly for 12 weeks or placebo. The objectives of this study were to evaluate the toxicity of TP-1 in this patient population and to make observations on clinical response as measured by time to second opportunistic infection (OI) and changes in laboratory parameters of immune function. The study demonstrates that TP-1 can be administered safely. There were no differences, however, in time to second OI or overall survival between patient groups. In addition, no change in the immune function could be detected in patients receiving thymostimulin.

ISSN:0735-7907    

DOI:10.3109/07357908909039841

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractAmmonium sulfate (AS) precipitation by consecutive steps at 10% to 50% saturation has been utilized for fractionation of cytoplasmic estrogen receptor (ER) and progesterone receptor (PgR). The highest percentage of both receptor activities are confined mainly in two fractions at AS saturation from 20% to 30% and 30% to 40%. The total percentages of activity of the cytoplasmic ER and PgR salted out at 50% saturation are 77% and 53%, respectively. Precipitation of hormone-receptor complexes at 50% saturation for assay of ER and PgR can be achieved, but needs improvement for efficient salting out of the receptors. ER and PgR salted out in the AS pellet are much more stable for storage than in the cytosol.

ISSN:0735-7907    

DOI:10.3109/07357908909039842

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractSoluble tumor-associated antigens were isolated from Lewis lung carcinoma (3LL) cells by detergent solubilization and purified by affinity chromatography on peanut agglutinin (PNA)-agarose. Subcutaneous injection of PNA-binding glyco-related antigen into 3LL-bearing male C57BL/6 mice significantly augmented delayed-type hypersensitivity (DTH), and also inhibited the growth of the primary 3LL tumors. The effects of combined immunotherapy and chemotherapy with this antigen and cyclophosphamide (CY) were examined following excision of 3LL by determining the number of pulmonary surface nodules and wet weight of the lungs. Injection of PNA-binding glyco-related antigen and CY significantly inhibited pulmonary metastasis and prolonged the survival of the mice. The spleen cells obtained from mice with combined treatment showed higher neutralizing activity against 3LL cells than other groups. Therefore, combined immuno and chemotherapy may be useful in preventing metastasis.

ISSN:0735-7907    

DOI:10.3109/07357908909039843

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909039844

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909039845

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909039846

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractThe 1980 Graduate Medical Education National Advisory Committee (GMENAC) study projected that by the year 1990 a shortage of 700“hematologists/oncologists”would exist in this country (1). Subsequent estimates indicate manpower needs will be met by certified specialists and, if one includes noncertified specialists a surplus will exist in the near future (2). In addition to increased competition for patients, oncologists face changes in traditional third-party and governmental reimbursement policies as well as the proliferation of such managed care systems as health maintenance organizations (HMOs) and preferred provider organizations (PPOs). Such changes are altering the amounts, timeliness, and methods of physician reimbursement. Aside from concerns about personal payment, oncologists may wonder if such changes will affect the quality of patient care. This article discusses methods of payment for the oncologist's services and the implications that changes in the current system may have on quality of care. Because the managed care systems mentioned above (especially HMOs) provide the greatest challenge to traditional oncology practice, more discussion will be devoted to that topic than to traditional payment methods.

ISSN:0735-7907    

DOI:10.3109/07357908909039847

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

摘要:

AbstractHealth Maintenance Organizations (HMOs) have existed in the United States for at least 50 years. Recently their membership growth has increased markedly so that they currently care for millions of people in many locations in the United States. The growth of this form of medical care provides investigators with significant opportunities for research of all types. We will discuss some features of HMOs that facilitate research, concentrating on opportunities in the area of oncology. Our focus will be on not-for-profit HMOs, particularly ones in existence for a period of time sufficient to develop adequate numbers of members for study.

ISSN:0735-7907    

DOI:10.3109/07357908909039848

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908909039849

出版商:Taylor&Francis    

年代:1989

数据来源: Taylor